Thyrocare Technologies has announced a final dividend of Rs. 7.00 per equity share for the financial year 2025-26. Along with the dividend, the company reported significant leadership changes, including the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director, and CEO, and the appointment of new directors. The board also approved an investment of Rs. 5.50 crore in its subsidiary, Think Health Diagnostics, and proposed key alterations to its Memorandum of Association.
Financial Performance and Dividend Payout
The Board of Directors has recommended a final dividend of Rs. 7.00 per equity share for the fiscal year ended March 31, 2026. Including the interim dividend already paid, the total dividend for the year amounts to Rs. 9.33 per equity share on a post-bonus adjusted basis. The final payout is subject to shareholder approval at the upcoming Annual General Meeting.
Strategic Leadership Transitions
The company has confirmed the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director, and CEO for a five-year term beginning May 4, 2027, through May 3, 2032. Additionally, the Board has welcomed Mr. Uday Patel Kadam and Mr. Gaurav Verma as Non-Executive, Non-Independent Directors, effective May 8, 2026. These appointments follow the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, who stepped down from their respective board positions effective May 7, 2026.
Auditor Updates and Corporate Developments
Thyrocare is transitioning to M/s. Price Waterhouse Chartered Accountants LLP as its new Statutory Auditors for a five-year term starting from the conclusion of the 26th Annual General Meeting. The company has also appointed M/s. Jitender Navneet & Co. as Cost Auditors for the 2026-27 financial year.
Growth Investment and Operational Scope
To support its diagnostic expansion, the company has approved a capital infusion of up to Rs. 5.50 crore into its wholly-owned subsidiary, Think Health Diagnostics Private Limited. Furthermore, the company is updating its Memorandum of Association to align with current corporate legislation and to broaden its operational scope, enabling the firm to pursue a wider range of activities within the healthcare and diagnostic ecosystem, including digital health platforms and the sale of medical consumables.
Source: BSE
